Topical PDE4 inhibitors show efficacy in pediatric atopic dermatitis meta-analysis

This meta-analysis pooled data from 5 randomized controlled trials involving 1,877 pediatric patients with mild-to-moderate atopic dermatitis. The analysis compared topical phosphodiesterase 4 (PDE4) inhibitors against topical vehicle treatment, with outcomes assessed at weeks 2 and 4. The primary outcome was not specified.

For efficacy, PDE4 inhibitors were associated with higher Investigator Global Assessment response rates (OR: 3.56; 95% CI: 2.09 to 6.04; P = .005). Treatment success rates were increased at week 2 (OR: 4.09; 95% CI: 2.32 to 7.21; P < .00001) and week 4 (OR: 3.06; 95% CI: 1.52 to 6.18; P = .002). Eczema Area and Severity Index scores also favored PDE4 inhibitors (OR: -4.11; 95% CI: -4.83 to -3.39; P < .00001). All results are odds ratios; absolute numbers were not reported.

Regarding safety, there was no significant difference in overall adverse events between PDE4 inhibitors and vehicle (OR: 1.16; 95% CI: 0.93 to 1.44; P = .18). Data on serious adverse events, discontinuations, and tolerability were not reported. The analysis used a random-effects model when heterogeneity was high (I² >50%).

Key limitations include the lack of reported absolute risk reductions, which limits clinical interpretability of the odds ratios. The funding source and author conflicts of interest were not reported. The authors concluded PDE4 inhibitors 'might be' an effective and safe option. For practice, this meta-analysis suggests a potential role for topical PDE4 inhibitors in pediatric atopic dermatitis, but clinicians should consider the evidence strength and absence of absolute benefit metrics when making treatment decisions.